PDCD1 and non-small cell lung carcinoma: The representative ICB therapy, pembrolizumab, is a PD-1 inhibitor, which has been approved for the treatment of colorectal cancer (Powles et al., 2020), non-small cell lung cancer (NSCLC) (Mok et al., 2019) (Abbreviations and full names of tumors and targets was shown in Supplementary Table 1) and other cancer types.